Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.

Tim R H Read, Dianne L Carey, Patrick Mallon, Anne Mijch, Ruth Goodall, Fleur Hudson, Handan C Wand, Sean Emery

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)


To assess whether trial participants who ceased efavirenz (EFV) because of neuropsychiatric events had elevated plasma concentrations, we performed a retrospective case-control study. EFV levels were measured by high-performance liquid chromatography in stored plasma from 35 cases and 75 matched controls. All had taken EFV for at least 4 weeks. Median EFV concentrations did not differ (P = 0.77). Measurement of EFV levels in plasma collected at variable times after the last dose did not predict central nervous system intolerance.

Original languageEnglish
Pages (from-to)2222-2223
Number of pages2
Issue number16
Publication statusPublished - 23 Oct 2009

Cite this